Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: A commercial-stage biotechnology company focused on immunotherapy, endocrinology, urology, neurology, and orthopedics. Primary commercial operations are conducted through its subsidiary, Creative Medical Technologies, Inc. (CMT), which sells CaverStem and FemCelz disposable kits for treating erectile and female sexual dysfunction. The company is actively developing stem cell-based therapies for Type 1 Diabetes, chronic lower back pain, and other conditions.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $8,000 | $8,000 |
| Cost of Revenues | $3,200 | $3,200 |
| Gross Profit | $4,800 | $4,800 |
| Operating Expenses | $1,630,106 | $2,753,253 |
| Operating Loss | $(1,625,306) | $(2,748,453) |
| Net Loss | $(1,557,728) | $(2,599,272) |
| Net Loss Per Share (Basic & Diluted) | $(1.11) | $(1.84) |
| Cash and Cash Equivalents (Ending Balance) | $7,471,476 | |
| Total Assets | $7,989,706 | |
| Total Liabilities | $376,272 | |
| Working Capital | ~$7,227,684 |
Material Changes vs. Prior Period
- Revenue: Generated $8,000 in revenue for the three and six months ended June 30, 2024, compared to $0 in the same periods in 2023.
- Research and Development (R&D): R&D expenses increased significantly by 199% ($615,269) for the quarter and 114% ($718,632) for the six months compared to the prior year. This increase is attributed to clinical trial costs for Type 1 Diabetes (CELZ 201 CREATE-1) and Chronic Lower Back Pain (CELZ-201 ADAPT).
- Selling, General and Administrative (SG&A): SG&A expenses decreased by 21% for the quarter and 17% for the six months compared to the prior year, driven by reductions in marketing, marketing-based compensation, and professional fees.
- Liquidity: Cash balances increased from $3.47 million at December 31, 2023, to $7.47 million at June 30, 2024. This increase was primarily due to the redemption of $6.52 million in investments (certificates of deposit and US Treasuries).
- Net Loss: Net loss widened to $1.56 million for the quarter and $2.60 million for the six months, compared to $1.10 million and $2.15 million in the prior year periods, respectively.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- Clinical Progress: The company received FDA Orphan Drug Designation for Brittle Type 1 Diabetes in March 2024. Patient recruitment for the Phase I/II clinical trial for Type 1 Diabetes (CELZ-201 CREATE-1) began in September 2023. In June 2024, the company announced the successful generation of human iPSC-derived Islet Cells producing human insulin.
- Lower Back Pain Trial: In Q2 2024, the company selected a clinical trial site and CRO, and launched patient recruitment for the Phase I/II trial of AlloStemSpine for chronic lower back pain.
- Capital Resources: Management states the company has sufficient cash to fund operations for the next 12 months based on current burn rates.
Risks and Contingencies:
- Capital Needs: The company has a limited operating history and minimal revenues. Future success depends on raising additional capital for clinical trials and commercialization.
- Related Party Transactions: Significant licensing agreements exist with related parties (e.g., Jadi Cell, LLC, CMH), involving royalty payments and milestone obligations.
- Regulatory Risk: Success is contingent on FDA approvals for investigational new drugs (INDs) and clinical trial outcomes.
- Market Risk: The company faces competition from well-funded entities and risks associated with rapid technological changes in the biotechnology sector.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $7.47 million cash balance against the reported operating loss of ~$2.6 million for the six-month period.
- Clinical Trial Milestones: Confirm the status and enrollment numbers for the Type 1 Diabetes (CELZ-201 CREATE-1) and Lower Back Pain (CELZ-201 ADAPT) trials.
- Related Party Obligations: Review the specific terms of the licensing agreements with Jadi Cell and CMH, particularly regarding future royalty payments and milestone triggers.
- Stock Repurchase Program: Note the company has repurchased 93,000 shares YTD under a $2 million program, with approximately $1.58 million remaining available.
- Revenue Sustainability: Assess whether the $8,000 in revenue is a recurring trend or a one-time event, given the historical lack of revenue.